Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
  • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
  • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
  • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
  • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D307/80—Radicals substituted by oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/08—Bridged systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• the present invention relates, in general, to new heterocyclic derivatives as well as to their process of preparation.
• the invention thus relates to new benzofuran or benzothiophene derivatives of general formula:
• A represents an alkylene group, linear or branched, in C ⁇ Cs, optionally substituted by a hydroxyl group, or A represents a group of general formula:
• R 30 and R 31 taken together, represent a carbonyl group with the carbon to which they are attached, or represent a group of general formula:
• R 29 represents a C r C 4 alkylene group
• T represents hydrogen or a CC 4 alkyl radical
• R represents:
• R 4 represents a linear or branched C-
• R 5 represents hydrogen or an alkali metal atom
• R 6 and R 7 identical or different, represent hydrogen or an alkyl radical, linear or branched, in C r C 4 or R 6 and R 7 , when taken together, represent a C 2 -C 6 alkylene chain, a ketone group of general formula:
• R 8 represents a C 1 -C 4 alkyl group
• R 9 represents hydrogen or a C r C 4 alkyl radical
• R 10 represents a linear or branched C 1 -C 4 alkylene group
• Ru represents hydrogen or a C 1 -C 4 alkyl radical
• R 12 represents a C r C 4 alkyl radical or R ⁇ and R 12 , when taken together, represent a C 2 -C 6 alkylene chain, a group of general formula:
• R 32 and R 33 identical or different, represent a linear or branched C r C 4 alkyl group
• R represents hydrogen, an alkyl group in linear or branched, cycloalkyl C 3 -C 6, benzyl or phenyl optionally substituted by one or more substituents selected from halogen atoms, alkyl groups C r -C 4 alkoxy groups or C r C 4, or R ⁇ represents a group of general formula:
• R 21 represents a CC 4 alkylene group, linear or branched
• R 22 represents a C 1 -C 4 alkyl group, linear or branched
• R 1 represents a group of general formula:
• R 23 represents a linear or branched C ⁇ Ce alkylene group
• R 24 represents a linear or branched CrC 4 alkylene group
• R 25 represents a linear or branched C 1 -C 4 alkyl group
• R 2 and R 3 when taken together, represent a linear or branched C 3 -C 10 alkylene group or, with the nitrogen atom to which they are attached, represent a group of general formula: in which :
• R 27 . and R 28 identical or different, represent hydrogen or a linear or branched C r C 4 alkyl group, or
• R 26 represents hydrogen or a linear or branched C r C 4 alkyl group
• R 27 and R 28 when taken together, represent a linear or branched C 1 -C 4 alkylene group, these alternatives R 2 and R 3 identical or different and R 2 and R 3 taken together being represented in formula (1) by the symbol ⁇ ⁇
• benzofuran or benzothiophene derivatives according to the invention are characterized in that A represents a C r C 5 linear or branched alkylene group.
• the benzofuran or benzothiophene derivatives according to the invention are characterized in that R. represents hydrogen, a linear or branched C r C 6 alkyl group, C 3 -C 6 cycloalkyl, benzyl or phenyl optionally substituted by one or more substituents selected from halogen atoms, CC 4 alkyl groups or C r C 4 alkoxy groups.
• the invention relates to new benzofuran or benzothiophene derivatives, which can be represented by the general formula:
• A represents an alkylene group, linear or branched, at G, -C 5 ,
• T represents hydrogen or a C r C 4 alkyl radical
• R represents:
• R 4 represents a C r C 6 alkyl or C 3 -C 6 cycloalkyl group
• R 6 and R 7 identical or different, represent hydrogen or an alkyl radical, linear or branched, in C r C 4 or R 6 and R 7 , when taken together, represent a chain C 2 -C 6 alkylene, a ketone group of general formula:
• R 8 represents a C r C 4 alkyl group, an oxime group of general formula:
• R 9 represents hydrogen or a C 4 -C 4 alkyl radical, • a carboxyl group of general formula:
• R 10 represents a linear or branched alkylene group at 0, -0 .., R represents hydrogen or an alkyl radical in CC 4
• R 12 represents an alkyl radical in C r C 4 or R ⁇ and R 12 , when taken together, represent a C 2 -C 6 alkylene chain
• R 1 represents hydrogen, a linear or branched C 4 -C 6 alkyl group, C 3 -C 6 cycloalkyl, benzyl or phenyl optionally substituted by one or more substituents selected from halogen atoms, C 1 -C 4 alkyl groups or C r C 4 alkoxy groups )
• R 2 and R 3 identical or different, represent hydrogen, an alkyl group, linear or branched, in C ⁇ Ce or a cycloalkyl group in C 3 -C 6) or R 2 and R 3 , when taken together represent a linear or branched C 3 -C 10 alkylene group, these alternatives R 2 and R 3 identical or different and R 2 and R 3 taken together being represented in formula (1-1) by the symbol
• Another class of preferred compounds of formula (1) is that in which
• Compounds of formula (1) can be in the form of optical or geometric isomers, for example the compounds in question in which R 2 and R 3l taken with the nitrogen atom to which they are attached, represent a diethylpiperidino group or in which R represents a group (e).
• the invention relates both to the individual isomers of the compounds of formula (1) as well as to their mixtures, in particular the racemic mixture.
• the invention also relates to the pharmaceutically acceptable salts of the compounds of formula (1) formed from an organic or inorganic acid.
• organic salts include the oxalate, maleate, fumarate, methanesulfonate, benzoate, ascorbate, pamoate, succinate, hexamate, bismethylenesalicylate, ethanedisulfonate, acetate, propionate, tartrate, salicylate, citrate, gluconate, lactate, malate , cinnamate, mandelate, citraconate, aspartate, palmitate, stearate, itaconate, glycolate, p-aminobenzoate, glutamate, benzenesulfonate, p-toluenesulfonate and theophylline acetate as well as the salts formed from an amino acid such as lysine salt or histidine.
• inorganic salts of this kind mention may be made of the hydrochloride, hydrobromide, sulphate, sulphamate, phosphate and nitrate.
• the compounds of the invention have been found to have remarkable pharmacological properties, in particular anti-arrhythmic properties since they have been shown to be able to suppress or prevent disorders of the ventricular and atrial rhythm.
• Most of the compounds of the invention have electrophysiological properties of classes 1, 2,3 and 4 of the Vaughan-Williams classification which confer non-competitive bradycardising, anti-hypertensive and anti-adrenergic properties.
• most of the compounds have also revealed antioxidant properties, an affinity for sigma receptors and an ability to increase the synthesis of NO.
• these compounds of the invention demonstrate inhibitory properties of various hormonal agents such as for example angiotensin II, arginine vasopressin, neuropeptide Y or Pendothelin.
• the compounds in question are capable of making the compounds in question very useful in the treatment of certain pathological syndromes of the cardiovascular system, in particular in the treatment of angina pectoris, hypertension, arrhythmia, in particular atrial, ventricular or supraventricular, cerebral circulatory failure.
• the compounds of the invention may be used in the treatment of heart failure, of myocardial infarction whether or not complicated by heart failure or for the prevention of post-infarction mortality.
• the compounds of the invention could be useful as potentiators of anticancer agents.
• the invention also relates to a medicament, characterized in that it comprises a compound derived from benzofuran or benzothiophene, or a pharmaceutically acceptable salt of the latter, according to the invention.
• the invention also relates to pharmaceutical or veterinary compositions containing as active principle, at least one compound of the invention, in combination with a suitable pharmaceutical vehicle or excipient.
• the daily dosage for a human being weighing 60 kg will be between 2 and 2000 mg of active principle, in particular between 50 and 500 mg of active principle.
• the compounds of formula (1) can be prepared according to the following methods:
• R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f), by reacting a compound of general formula:
• R ' represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f) and R ⁇ T and X have the same meaning as previously, with a halide of general formula: in which A, R 2 , R 3 , W, W "and Z have the same meaning as above and Hal represents a halogen atom such as for example chlorine or bromine, the reaction taking place in the presence of a Lewis acid such as aluminum chloride, stannic chloride, ferric chloride or silver trifluoromethanesulfonate, which provides the desired compounds of formula (1) in the form of the free base.
• a Lewis acid such as aluminum chloride, stannic chloride, ferric chloride or silver trifluoromethanesulfonate
• the above reaction takes place in an apolar solvent such as a halogenated compound, for example dichloromethane or dichloroethane and at a temperature between 5 ° C. and the reflux temperature.
• a halogenated compound for example dichloromethane or dichloroethane
• R represents a group (b)
• a basic agent namely an alkali metal hydroxide, for example sodium hydroxide
• a compound of formula (1) above in which R represents a group (a) that is to say a compound of general formula:
• R. ,, R 2 , R 3 , R 4 , T, W, W, X and Z have the same meaning as above, which provides, in the form of a free base, the compounds of formula (1) in which R 5 represents an alkali metal atom, compounds which are treated, if necessary, with a strong acid, for example hydrochloric acid, which provides, in the form of a free base, the desired compounds of formula (1 ) in which R 5 represents hydrogen.
• a strong acid for example hydrochloric acid
• R represents the cyano group
• R 2 and R 3 which are identical, each represents hydrogen, by treating, with triphenylphosphine, an azide of general formula:
• R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f), and A represents an alkylene group, linear or branched, C 3 -C 5 or a group (h), by reacting a ketone compound of general formula:
• a ' represents a linear or branched C 3 -C 5 alkylene group
• the reaction takes place at a temperature between room temperature and the reflux temperature of the solvent and in a polar solvent such as N, N-dimethylformamide, acetonitrile, methyl ethyl ketone or dimethyl sulfoxide or an apolar solvent such as benzene or toluene.
• a polar solvent such as N, N-dimethylformamide, acetonitrile, methyl ethyl ketone or dimethyl sulfoxide or an apolar solvent such as benzene or toluene.
• a catalyst preferably sodium or potassium iodide.
• n ' is 0 or is an integer between 1 and 3, with metachloroperbenzoic acid to obtain the epoxide of general formula:
• R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f)
• R 2 represents hydrogen or a group alkyl, linear or branched, in -Ce
• R 3 represents an alkyl group, linear or branched, in C r C 6 , by reacting an amine of general formula:
• R ' 2 represents hydrogen or an alkyl radical in and this, in the presence of sodium triacetoxyborohydride, to provide the desired compounds of formula (1) in the form of the free base.
• R 1f R 2 , R 3 , T, W, W, X and Z have the same meaning as above, are themselves intermediates of synthesis for the preparation of other compounds of formula (1).
• R represents a group (c)
• R represents a group (c)
• a compound of formula (11) after protection of the amino function when R 2 and / or R 3 represent hydrogen and this, preferably in a halogenated hydrocarbon as solvent and generally at reflux temperature, with a halogenating agent such as thionyl chloride, phosgene or oxalyl chloride to obtain an acyl halide which is then treated, preferably at temperature ambient, with a compound of general formula:
• R represents a group (a)
• R represents a group (a)
• a compound of formula (11) after protection of the amino function when R 2 and / or R 3 represent hydrogen, preferably in a halogenated hydrocarbon as solvent and generally at the reflux temperature, with a halogenating agent such as thionyl chloride, phosgene or oxalyl chloride to obtain an acyl halide that then treated, preferably at a temperature between room temperature and the reflux temperature, with an alcohol of general formula:
• R represents a group (f): a) if this group (f) is of the primary dialkylaminoalkyl type, the reaction is preferably carried out in a polar solvent such as N, N-dimethylformamide and usually at a temperature between 30 and 50 ° C, a compound of formula (11) after protection of the amino function when R 2 and / or R 3 represent hydrogen, with an alcohol of general formula:
• R ⁇ and R 12 have the same meaning as above and R 10 represents a linear alkylene group in GC 4 , the reaction taking place in the presence of carbonyl diimidazole and of 1,8-diazabicyclo [5.4.0] undec-7ene, then the compound formed is deprotected, if necessary, which provides, in the form of a free base, the desired compounds of formula (1), b) if this group (f) is of the secondary or tertiary dialkylaminoalkyl type, it is reacted, preferably in an aprotic solvent such as a halogenated hydrocarbon and generally at the reflux temperature of the medium, a compound of formula (11) after protection of the amine function when R 2 and / or R 3 represent hydrogen, with a halogenating agent such as thionyl chloride, to obtain an acyl halide which is then treated, preferably at room temperature, with an alcohol of formula (14) above in which R -, -, and R 12 have the same meaning as
• the protection of the amine function of the compound of formula (10), that is to say the protection envisaged when R 2 and / or R 3 represent hydrogen can be obtained for example by treatment with a compound allowing the fixation of an easily eliminable group in particular by means of 9-fluorenylmethylchloroformate and deprotection takes place thereafter by treatment with a secondary amine, for example piperidine or diethylamine in a suitable solvent, for example N, N-dimethylformamide.
• the reaction is preferably carried out in an aprotic solvent such as an aromatic hydrocarbon, for example benzene or toluene and usually at the reflux temperature of the medium, a compound of formula (15) with a (trialkyl in GC 4 ) azido tin, for example tributylazido tin, which provides, in the form of a free base, the desired compounds of formula (1).
• an aprotic solvent such as an aromatic hydrocarbon, for example benzene or toluene and usually at the reflux temperature of the medium
• a compound of formula (15) with a (trialkyl in GC 4 ) azido tin for example tributylazido tin
• the compounds of formula (1) can be obtained in which
• R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f), and in which R 2 and R 3 , which are different, each represent a linear or branched C r C 6 alkyl group OR a C 3 -C 6 cycloalkyl group, by transforming a secondary amine comprising a -NHR 3 group in which R 3 is different from hydrogen to a tertiary amine, by reaction d '' a compound of general formula:
• R R ', T, X, W, W and Z have the same meaning as above and R' 3 represents an alkyl group, linear or branched, in G- C 6 or C 3 -C 6 cycloalkyl, with a halide of general formula:
• Hal represents a halogen atom, preferably bromine and R " 2 represents a linear or branched CC 6 alkyl group or a C 3 -C 6 cycloalkyl group
• a basic agent such as an alkali metal carbonate or hydroxide and preferably at reflux temperature, which provides the desired compounds of formula (1) in the form of the free base.
• the compounds of formula (2) can be obtained according to different methods in relation to their chemical structure and more particularly in relation to the position of the group R '.
• T and X have the same meaning as above, first with an alkali metal iodide and an oxidizing agent such as an alkali metal hypochlorite, for example sodium hypochlorite, then with an alcohol of general formula:
• an appropriate catalyst such as a palladium derivative, for example tetrakis (triphenylphosphine) palladium and cuprous iodide, which provides the desired compounds of formula (2).
• the preparation of the ester of formula (22) can be carried out according to the method described above but starting from an acid of formula (20) in the form of acyl halide obtained after treatment of the derivative d benzoic acid of formula (20) using a halogenating agent, for example thionyl chloride, phosgene or oxalyl chloride.
• a halogenating agent for example thionyl chloride, phosgene or oxalyl chloride.
• T and X have the same meaning as above and R represents the cyano group, a group (a) or a group (f), with the anhydride of trifluoromethanesulfonic acid in the presence of pyridine, to obtain a compound of formula General
• this compound of formula (26) is then cyclized in the presence of boron tribromide at a temperature below -50 ° C., which provides the heterocyclic compounds of general formula:
• R represents the cyano or carboxylic group, which provides either desired compounds of formula (2) when R "represents the cyano group or an acid when R" represents the carboxylic group, d) this acid is esterified with an alcohol of formula (21) or of formula (14), which provides the desired compounds of formula (2).
• R '. ,, T and X have the same meaning as above, b) reacting the compound thus formed with an acetylene derivative of formula (23) and this, in the presence of an appropriate catalyst such as a derivative palladium, for example dichloro bis- (triphenylphosphine) palladium and an acid acceptor such as triethylamine, to form the compounds of general formula:
• an appropriate catalyst such as a derivative palladium, for example dichloro bis- (triphenylphosphine) palladium and an acid acceptor such as triethylamine
• the compounds of formula (2) in which R 'is located in position 5 and represents the cyano group, a group (a) or a group (f), and R ⁇ is in position 2 can also be prepared as follows:
• R ' represents a group (a): a) a benzoate of general formula is first treated:
• R 15 represents a group (a) or (f), with methanesulfonic acid in the presence of phosphorus pentoxide and hexamethylenetetramine, to give a formyl derivative of general formula :
• this compound (36) is cyclized in the presence of benzenesuflonyl chloride or of p-toluensulfonyl and of an acceptor acid such as triethylamine, which gives the desired compounds of formula (2).
• R ' represents the cyano group: a) a formyl derivative of general formula is first treated:
• R 16 represents a cyano or formyl group and T and X have the same meaning as above and this, with methyl iodide in the presence of an alkali metal hydride to give a compound of general formula:
• R 1 f X and T have the same meaning as above and R 17 represents the methoxycarbonyl or carboxylic group, a mixture which is treated with methanol in the presence of a strong acid such as sulfuric acid, which provides the desired compounds of formula (2) wherein R 'represents the methoxycarbonyl group.
• the other compounds of formula (2) that is to say the compounds of formula (2) in which R ′ located in position 7 represents a group (a), with the exception of the methoxycarbonyl group, or a group ( f), can be obtained by saponifying an ester of formula (2) in which R ′ located in position 7 represents the methoxycarbonyl group and this, in the presence of a basic agent such as an alkali metal hydroxide to give a salt which it is acidified with a strong acid such as hydrochloric acid to give a 7-carboxy-benzofuran derivative which is esterified with an alcohol of formula (14) or an alcohol of general formula:
• the compounds of formula (2) in which R ′ represents the formyl group can be prepared by oxidizing with oxalyl chloride, an alcohol of general formula:
• R 9 has the same meaning as previously, optionally in the form of its salts, and this, in an acid-capturing solvent, for example pyridine, to form the desired compounds.
• an acid-capturing solvent for example pyridine
• R 8 has the same meaning as above, which provides the desired compounds.
• the compounds of formula (3) are either known products or products which can be prepared by known methods.
• the compounds of formula (3) in which A represents a C 3 -C 5 alkyl radical can be obtained by means of the following series of steps: a) acylation of a compound of general formula:
• esterification of the acid of formula (56) or of a halide thereof obtained after treatment, for example with chloride of thionyl this esterification being carried out using an alcohol of general formula: in which R 18 represents a CC 4 alkyl group, to obtain an ester of general formula:
• the compounds of formula (5) can be prepared starting from an ester of formula (1) in which R represents a group (a):
• the compounds of formula (6) can be obtained by reacting a ketone compound of general formula:
• the compounds of formula (7) can be prepared starting from a compound of formula (2) by reaction of this compound with a dihalide of general formula:
• Hal' represents a halogen atom such as chlorine or bromine, preferably bromine, the reaction taking place in the presence of a Lewis acid such than aluminum chloride, stannic chloride, ferric chloride or silver trifluoromethanesulfonate, which provides the desired compounds.
• the compounds of formula (7) in which R 'represents a group (a) or a group (f) can be obtained by saponifying an ester of formula (7) in which R' represents a group -CO 2 R " 4 in which R" 4 represents a GC 10 alkyl or C 3 -C 6 cycloalkyl group, this, in the presence of a basic agent generally an alkali metal hydroxide, by treating the salt thus formed with a strong acid such as hydrochloric acid, by reacting the acid thus formed with a halogenating agent such as oxalyl chloride, and finally by esterifying the acyl halide thus formed with an alcohol of formula (13) or (14 ) to obtain the desired compounds.
• the compounds of formula (62) can be prepared in an identical manner to those described above for the synthesis of the compounds of formula (7).
• the compounds of formula (63), on the other hand, can be prepared by halogenating an acid of formula (56) using an appropriate agent such as thionyl chloride, phosgene or oxalyl chloride, which provides the desired compounds.
• amines of formula (8) are known and described in patents US4831054 or EP471609 or which can be prepared by the methods described therein.
• Benzofuran or benzothiophene derivatives are already known comprising an aminoalkyl-benzoyl chain and variously substituted on the monocycle.
• Such compounds have been described, for example, in patents or patent applications EP651998, EP657162, WO9510513 or WO9725033 where they are presented as having cholesterol-lowering, thrombin inhibiting, estrogen agonists or bone loss inhibiting properties.
• benzofuran or benzothiophene derivatives comprising an aminoalkylbenzoyl chain as well as other groups attached to the heterocycle via a carbon atom, have very interesting pharmacological properties including antiarrhythmic properties while providing very good metabolic stability, very acceptable solubility and very good bioavailability by the oral route.
• Rats divided into lots, are first anesthetized with sodium pentobarbital (60 mg / kg intraperitoneally) then they are intubated and kept under assisted respiration. They then place a cannula for intravenous administration in the right jugular vein, an intravenous dose of the test compound is administered and 5 minutes later, a ligature loop is placed around the left anterior descending coronary artery and in the immediate vicinity of His origin. This artery is then occluded for 5 minutes by traction on the ends of the ligature so as to induce reperfusion by releasing the tension.
• sodium pentobarbital 60 mg / kg intraperitoneally
• the arrhythmias induced by this reperfusion are then evaluated. A similar test was performed orally.
• the compound to be studied is administered 120 minutes before ligation of the left anterior descending coronary artery.
• the results of these tests have shown that the compounds of the invention protect animals treated significantly up to 100% at doses between 0.3 and 10 mg / kg intravenously and 10 to 90 mg / kg orally.
• the aim of this test is to determine the capacity of the compounds of the invention to reduce the increase in blood pressure induced by phenylephrine (anti- ⁇ effect) and the acceleration of the heart rate induced by l isoprenaline (anti- ⁇ effect) in dogs previously anesthetized with pentobarbital and chloralose.
• the doses of phenylephrine and isoprenaline thus determined are injected alternately every 10 minutes and after obtaining 2 successive reference responses, a dose of the compound to be studied is administered intravenously.
• the percentage reduction, by the test compound, of the induced acceleration of the heart rate is recorded.
• Atrial fibrillation The aim of this test is to evaluate the effectiveness of the compounds of the invention with regard to atrial fibrillation induced by permanent stimulation of the vagus nerve in the anesthetized dog according to the method described in Circulation 1993; 88: 1030-1044.
• the test compounds are administered at cumulative doses of 3 and 10 mg / kg as slow 10-minute intravenous infusions during an episode of sustained atrial fibrillation.
• the compounds of the invention generally convert 100% of the atrial fibrillations into sinus rhythm and prevent reinduction in 50 to 100% of the cases. At this dose, significant increases in the cardiac period are observed as well as effective atrial refractory periods for different basal values of the cardiac period. IV. Inhibiting effects of the neuro-hormonal system
• the purpose of this test is to search for the inhibitory effects of the compounds of the invention vis-à-vis the vasoconstrictor effects induced by different peptides such as norepinephrine (NA), angiotensin II (A-II), arginine vasopressin (AVP), neuropeptide Y (NPY) and endothelin (ET) and also vis-à-vis the tachycardic effects induced by isoprenaline (Iso) in the alert rat.
• NA norepinephrine
• A-II angiotensin II
• AVP arginine vasopressin
• NPY neuropeptide Y
• ET endothelin
• an arterial catheter (right carotid artery) for measuring blood pressure and a venous catheter (right jugular vein) for injection of the products are implanted 24 hours before the test. to study.
• the rats are placed in cylindrical boxes and the arterial catheter is connected to a pressure sensor via a rotary joint on a pendulum. This pressure sensor is itself connected to a polygraph for recording blood pressure.
• the various peptic agonists are first dissolved in 0.9% physiological saline and the compound to be studied in an appropriate solvent. These bolus peptides are then injected in a volume of 0.05 ml / kg, 30 and 10 minutes before the intravenous administration of 0.1 ml / kg of a solution of the compound to be studied or of solvent. These peptide injections are then repeated 10, 30, 60 and 120 minutes after the administration of the compound to be studied. Depending on the duration of action of the compound to be tested, it is optionally possible extend these injections every 30 minutes without ever exceeding 5 hours in total.
• the variations in blood pressure after administration of a given peptide are then evaluated by measuring, at different times, the difference between the maximum effect induced by the peptide agonist and the basal value of blood pressure.
• the compounds of the invention antagonize in a dose-dependent manner the vasoconstrictor effects induced by NA, A-11 and AVP. They also antagonize the effects induced by NPY and by ET and the increase in heart rate induced by Iso. At the highest doses, the maximum inhibition obtained after 15 minutes varies between 40 and 80% and the duration of action is at least greater than or equal to 30 minutes.
• the toxicity of the compounds of the invention has been found to be compatible with their use in therapy.
• compositions according to the invention can be presented in any form suitable for administration in human or veterinary therapy.
• the pharmaceutical compositions of the present invention can be formulated for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal or rectal administration.
• this may take the form, for example, of a tablet, a dragee, a capsule, a capsule, a powder, a suspension, syrup or granules for oral administration, a suppository for rectal administration or a solution or suspension for parenteral administration.
• compositions of the invention may comprise, per administration unit, for example from 50 to 500 mg by weight of active ingredient for oral administration, from 50 to 200 mg of active ingredient for rectal administration and from 50 150mg of active ingredient for parenteral administration.
• the pharmaceutical or veterinary compositions of the invention will be prepared by combining at least one of the compounds of formula (1) or a pharmaceutically acceptable salt thereof.
• compound with an appropriate excipient the latter which may consist, for example, of at least one ingredient selected from the following substances: lactose, starches, talc, magnesium stearate, polyvinylpyrrolidone, alginic acid, colloidal silica, distilled water, benzyl alcohol or agents sweeteners.
• these can be treated in such a way that they exhibit prolonged or delayed activity and that they continuously release a predetermined quantity of active principle.
• a reaction medium is formed from 4.91 g (16 mmol) of compound obtained in the previous step and from 50 ml of N, N-dimethylformamide to which 2.66 g of n-hexyne, 19 ml of piperidine are added. , 0.340 g of dichloro bis- (triphenylphosphine) palladium and 0.087 g of cuprous iodide. It is heated to 90 ° C for 2 hours, cooled and concentrated. Extracted with ethyl acetate and washed with dilute hydrochloric acid and then with water. It is then purified by chromatography on silica (eluent: dichloromethane / heptane 50/50).
• reaction medium is kept at room temperature for 15 hours and then evaporated. It is taken up in diethyl ether and then washed with water and then with a solution of sodium chloride.
• N-dimethylformamide are dissolved 45 g (0.158 mol) of 2-methoxy-3-trifluoromethanesulfonyloxy-benzaldehyde and 26 g (36.36 ml; 0.317 mol) of 1-hexyne. 79.58 g (109.6 ml; 0.788 mole) of triethylamine and 5.53 g (0.0079 mole) of dichloro bis- (triphenylphosphine) palladium are added. The reaction medium is heated to 90 ° C for 2 hours, diluted with an aqueous hydrochloric acid solution and extracted with diethyl ether. Wash with water and sodium chloride solution. Then purified by chromatography on silica (eluent: dichloromethane / hexane 5/5).
• A. Isopropyl 3-Methoxy-4-trifluoromethanesulfonyloxy-benzoate 2.1 g (0.01 mol) of isopropyl 3-methoxy-4-hydroxy-benzoate and 0.3 g (1.1 equivalents) of pyridine are introduced into 20 ml of dichloromethane. Then added dropwise between 0 ° and 5 ° C, a solution of 3.1 g (1.1 equivalent) of trifluoromethanesulfonic anhydride in 10 ml of dichloromethane. The mixture is left to return to ambient temperature, the mixture is stirred for 0.5 h at this temperature and evaporated. It is extracted with ethyl acetate and washed with water, dilute hydrochloric acid, a solution of sodium bicarbonate, water and finally a saturated solution of sodium chloride.
• dichloromethane 58 ml of dichloromethane are introduced and then 16.21 g (0.122 mole) of aluminum chloride and 9.8 g (0.125 mole) are added acetyl chloride.
• 20 g (0.118 mole) of 4-chlorobutylbenzene and 20.3 g (0.26 mole) of acetyl chloride are then added dropwise and at a temperature of 0 ° to 5 ° C.
• the mixture is stirred for 2 hours in an ice bath and then the reaction medium is poured onto an ice / water / hydrochloric acid mixture.
• the mixture is stirred for 15 minutes and then extracted with dichloromethane. It is then washed with water until neutral pH and then with sodium chloride.
• 1.9 g of dimethylhydroxylamine are added cold to 3 g of the compound obtained in step A above in DCM.
• 1.9 g of diisopropylethylamine (DIPEA) in DCM are added dropwise over 20 minutes. Leave to return to room temperature.
• the DCM is evaporated and then taken up with water and ethyl acetate. It is extracted three times with ethyl acetate and then washed twice with water and then with an aqueous NaCl solution. Dried over Na 2 SO 4 , concentrated, then purified by chromatography on silica (eluent: ethyl acetate / DCM).
• 1.5 g of the compound obtained in step C above are mixed with 1.5 g of dibutylamine and 30 ml of acetonitrile, which are brought to 60 ° C. for 60 hours. Evaporated and placed directly on a silica column for purification (eluent: DCM / ethyl acetate then DCM / methanol).
• Example 46 Solvent: DMSO at 2.5 ppm ⁇ (ppm): 0.8; triplet; 3H, CH 3 0.9; triplet; 6H, 2CH 3 1 to 1.8; massive; 18H, 2CH 3 , 6CH 2 1.95; multiplet; 2H, CH 2 2.75; triplet; 4H, 2CH 2 3; multiplet; 6H; 3NCH 2
• a capsule was prepared containing the following ingredients:

Priority Applications (27)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8853674

Family Applications (1)

Country Status (36)

Cited By (1)

Families Citing this family (20)

Citations (7)

Family Cites Families (7)

• 2000
  • 2000-08-23 FR FR0010834A patent/FR2813306B1/fr not_active Expired - Fee Related
• 2001
  • 2001-08-21 WO PCT/FR2001/002640 patent/WO2002016339A1/fr active IP Right Grant
  • 2001-08-21 AU AU2001284149A patent/AU2001284149B2/en not_active Ceased
  • 2001-08-21 ME MEP-2008-230A patent/ME00106B/me unknown
  • 2001-08-21 EP EP01963113A patent/EP1315709B1/fr not_active Expired - Lifetime
  • 2001-08-21 SK SK216-2003A patent/SK288126B6/sk not_active IP Right Cessation
  • 2001-08-21 HU HU0302968A patent/HU229456B1/hu not_active IP Right Cessation
  • 2001-08-21 NZ NZ523446A patent/NZ523446A/xx not_active IP Right Cessation
  • 2001-08-21 ME MEP-230/08A patent/MEP23008A/xx unknown
  • 2001-08-21 AT AT01963113T patent/ATE469138T1/de active
  • 2001-08-21 IL IL15363201A patent/IL153632A0/xx active IP Right Grant
  • 2001-08-21 JP JP2002521440A patent/JP5081363B2/ja not_active Expired - Fee Related
  • 2001-08-21 CZ CZ20030521A patent/CZ304003B6/cs not_active IP Right Cessation
  • 2001-08-21 AU AU8414901A patent/AU8414901A/xx active Pending
  • 2001-08-21 ES ES01963113T patent/ES2346291T3/es not_active Expired - Lifetime
  • 2001-08-21 PT PT01963113T patent/PT1315709E/pt unknown
  • 2001-08-21 CN CNB018177670A patent/CN1246315C/zh not_active Expired - Fee Related
  • 2001-08-21 US US10/362,324 patent/US6949583B2/en not_active Expired - Lifetime
  • 2001-08-21 RS YU12903A patent/RS51603B/sr unknown
  • 2001-08-21 CA CA2415847A patent/CA2415847C/fr not_active Expired - Fee Related
  • 2001-08-21 KR KR1020037002618A patent/KR100911280B1/ko active IP Right Grant
  • 2001-08-21 EA EA200300062A patent/EA006237B1/ru not_active IP Right Cessation
  • 2001-08-21 DK DK01963113.4T patent/DK1315709T3/da active
  • 2001-08-21 OA OA1200300035A patent/OA12359A/fr unknown
  • 2001-08-21 PL PL362119A patent/PL219848B1/pl unknown
  • 2001-08-21 DE DE60142240T patent/DE60142240D1/de not_active Expired - Lifetime
  • 2001-08-21 BR BRPI0113425-6A patent/BR0113425B1/pt not_active IP Right Cessation
  • 2001-08-21 SI SI200130974T patent/SI1315709T1/sl unknown
  • 2001-08-21 MX MXPA03001463A patent/MXPA03001463A/es active IP Right Grant
  • 2001-08-22 TW TW090120633A patent/TWI290920B/zh not_active IP Right Cessation
  • 2001-08-23 AR ARP010104023A patent/AR032892A1/es not_active Application Discontinuation
• 2002
  • 2002-12-24 IL IL153632A patent/IL153632A/en not_active IP Right Cessation
• 2003
  • 2003-01-13 IS IS6677A patent/IS2821B/is unknown
  • 2003-01-28 ZA ZA200300744A patent/ZA200300744B/xx unknown
  • 2003-02-05 BG BG107527A patent/BG66240B1/bg unknown
  • 2003-02-17 MA MA27042A patent/MA26943A1/fr unknown
  • 2003-02-20 NO NO20030800A patent/NO328138B1/no not_active IP Right Cessation
  • 2003-07-25 HK HK03105391.1A patent/HK1053113A1/xx not_active IP Right Cessation
• 2010
  • 2010-08-17 CY CY20101100763T patent/CY1110738T1/el unknown
• 2011
  • 2011-12-14 JP JP2011273790A patent/JP5603849B2/ja not_active Expired - Fee Related

Patent Citations (7)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events